Nano Viricides (NNVC) to Ramp Manufacturing, Leases Facility with Increased Capacity

QualityStocks would like to highlight NanoViricides (OTCBB: NNVC), a development stage company that is creating special purpose nanomaterials for viral therapy. The company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them.

In the company’s news yesterday,

Nano Viricides announced it will lease new space for current Good Manufacturing Practices (cGMP) production of its nanoviricides drug candidates for the treatment of various viral diseases.

The company plans to lease the space with an option for a future purchase from Inno-Haven LLC, as it acts on its need to produce larger quantities of its drug candidates for upcoming toxicological studies.

If the studies are successful, the company said it will manufacture additional materials to conduct human clinical trials if and when approved by the U.S. Food and Drug Administration (FDA). The production of the materials needed for the studies will be performed under cGMP, which are FDA guidelines for human clinical trials.

“This is the least dilutive way to obtain the cGMP manufacturing and lab space we need while avoiding capital expenditure from the company’s current cash reserves,” Dr. Eugene Seymour, MD, MPH, CEO of the NanoViricides stated in the press release. “We are now on our way to clearing a major hurdle in our path toward FDA submissions and human clinical development of our drug candidates.”

Inno-Haven has agreed to purchase certain facilities that will support NanoViricide’s objectives. Inno-Haven is owned by NanoViricides president and chairman, Anil R. Diwan, PhD, who plans to finance the purchase from his personal savings, personal borrowings, and a sale of stock of NanoViricides that he has received as a company founder.

The agreement calls for Dr. Diwan to sell up to 2 million shares of his stock over the next year; in exchange, Inno-Haven and Dr. Diwan have agreed to purchase and lease certain facilities to NanoViricides as needed.

TheraCour Pharma Inc., a drug development partner of NanoViricides controlled by Dr. Diwan, will also lease space in the same facility.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.